CN110974927A - Modified Xiaochaihu granules and preparation method thereof - Google Patents
Modified Xiaochaihu granules and preparation method thereof Download PDFInfo
- Publication number
- CN110974927A CN110974927A CN201911312896.6A CN201911312896A CN110974927A CN 110974927 A CN110974927 A CN 110974927A CN 201911312896 A CN201911312896 A CN 201911312896A CN 110974927 A CN110974927 A CN 110974927A
- Authority
- CN
- China
- Prior art keywords
- modified
- composition
- bupleurum
- granules
- ginger
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000008767 xiaochaihu Substances 0.000 title claims description 28
- 239000000203 mixture Substances 0.000 claims abstract description 60
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 36
- 235000008397 ginger Nutrition 0.000 claims abstract description 36
- 241000202726 Bupleurum Species 0.000 claims abstract description 27
- 241000510654 Bupleurum chinense Species 0.000 claims abstract description 23
- 241000132012 Atractylodes Species 0.000 claims abstract description 18
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 18
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 18
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 18
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims abstract description 18
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims abstract description 18
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 18
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 17
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 17
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 17
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 17
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 240000000038 Ziziphus mauritiana Species 0.000 claims abstract description 9
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000003153 chemical reaction reagent Substances 0.000 claims description 39
- 241000234314 Zingiber Species 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 238000000746 purification Methods 0.000 claims description 32
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 30
- 239000000284 extract Substances 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 23
- 238000001035 drying Methods 0.000 claims description 21
- 229920002498 Beta-glucan Polymers 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 19
- 241001132254 Bupleurum tenue Species 0.000 claims description 17
- 244000197580 Poria cocos Species 0.000 claims description 16
- 108010024636 Glutathione Proteins 0.000 claims description 15
- 229960003180 glutathione Drugs 0.000 claims description 15
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 abstract description 12
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 abstract description 12
- 229960003321 baicalin Drugs 0.000 abstract description 12
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 abstract description 12
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 abstract description 11
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 abstract description 11
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 abstract description 11
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 abstract description 11
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 abstract description 11
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 abstract description 11
- 229940015301 baicalein Drugs 0.000 abstract description 11
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 abstract description 11
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 abstract description 11
- LNOHXHDWGCMVCO-UHFFFAOYSA-N Wogonoside Natural products C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1OC1OC(C(O)=O)C(O)C(O)C1O LNOHXHDWGCMVCO-UHFFFAOYSA-N 0.000 abstract description 9
- LNOHXHDWGCMVCO-NTKSAMNMSA-N wogonin 7-O-beta-D-glucuronide Chemical compound C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LNOHXHDWGCMVCO-NTKSAMNMSA-N 0.000 abstract description 9
- 210000000952 spleen Anatomy 0.000 abstract description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract description 5
- 210000002784 stomach Anatomy 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 230000002411 adverse Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 244000273928 Zingiber officinale Species 0.000 abstract 2
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229930192014 saikosaponin Natural products 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 208000018556 stomach disease Diseases 0.000 description 3
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000019229 Spleen disease Diseases 0.000 description 2
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 208000027140 splenic disease Diseases 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000099774 Cuscuta salina Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004939 coking Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- -1 phospholipid compound Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to modified minor radix bupleuri granules and a preparation method thereof. The modified bupleurum composition of the invention is prepared by the following raw material medicaments by weight: 225-275 g of bupleurum chinense; 150-200 g of scutellaria baicalensis; 150-200 g of codonopsis pilosula; 150-200 g of rhizoma pinelliae praeparata; 150-200 g of ginger; 475-525 g of Chinese dates; 75-125 g of honey-fried licorice root; 75-125 g of dried ginger; 25-75 g of coptis chinensis; 225-275 g of tuckahoe; 150-200 g of bighead atractylodes rhizome. The modified radix bupleuri granules improve the contents of active ingredients of liquiritin, baicalin, berberine hydrochloride, wogonoside, baicalein and ammonium glycyrrhetate in raw medicaments, and play excellent roles of relieving shaoyang, harmonizing stomach, lowering adverse qi, tonifying spleen and relieving distension and fullness.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to modified minor radix bupleuri granules and a preparation method thereof.
Background
The Xiaochaihu decoction is an effective Chinese medicinal formula which is summarized according to symptoms of patients with spleen and stomach diseases at that time in the period of Sheng in east Han of China, is used for more than two thousand years till now and is called as a classic formula by later people. The classical formula consists of: bupleuri radix, Scutellariae radix, Ginseng radix, rhizoma Pinelliae Preparatum, radix Glycyrrhizae Preparata, rhizoma Zingiberis recens cutter and fructus Jujubae seed. However, with the long time span, the great difference of geographical environment, the change of human constitution, etc., the classical prescription can not satisfy the requirement of modern diseases.
Meanwhile, the chemical components of the traditional Chinese medicine are complex at present, the quality control difficulty is high, and the bupleurum tenue in the prior art is also considered to be low in effective components and purity, so that the drug effect is reduced. In the prior art, in order to improve the content of active ingredients of traditional Chinese medicines, various solubilization methods are adopted, however, different solubilization methods have certain defects, for example, a method of adopting a surfactant compound used in emulsification has the hidden trouble of aggravating toxic and side effects; moreover, the problems of drug leakage and poor stability are easy to occur if a phospholipid compound is used for coating; and the problems of low drug-loading rate and characteristic requirements on the size of drug molecules exist if a cyclodextrin embedding method is adopted. Therefore, it is necessary to provide bupleurum tenue which has excellent curative effect on spleen and stomach diseases so as to improve the application of the bupleurum tenue in spleen and stomach medicines.
Disclosure of Invention
The invention aims to provide modified minor bupleurum particles and a preparation method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a modified Xiaochaihu composition is prepared from the following raw material medicaments in part by weight:
225-275 g of bupleurum chinense;
150-200 g of scutellaria baicalensis;
150-200 g of codonopsis pilosula;
150-200 g of rhizoma pinelliae praeparata;
150-200 g of ginger;
475-525 g of Chinese dates;
75-125 g of honey-fried licorice root;
75-125 g of dried ginger;
25-75 g of coptis chinensis;
225-275 g of tuckahoe;
150-200 g of bighead atractylodes rhizome.
The raw material medicaments in the invention interact with each other, and have the effects of relieving shaoyang, harmonizing stomach, lowering adverse qi, tonifying spleen and relieving distension and fullness. The modified Xiaochaihu granules can be used for treating spleen and stomach diseases caused by the dysfunction of shaoyang pivot machine and the dysfunction of spleen and stomach ascending and descending, and the symptoms are dry mouth, bitter taste, abdominal distension, anorexia, vomiting, hiccup, belching and loose stool.
Further, the medicine is prepared from the following raw material medicines in parts by weight:
250g of bupleurum chinense;
167g of scutellaria baicalensis;
167g of codonopsis pilosula;
167g of rhizoma pinelliae praeparata;
167g of ginger;
500g of Chinese dates;
prepared licorice root 100 g;
100g of dried ginger;
50g of coptis chinensis;
250g of poria cocos;
167g of white atractylodes rhizome.
The invention provides a preparation method of the modified bupleurum composition, which comprises the following steps:
s1) taking the bupleurum chinense, the scutellaria baicalensis, the codonopsis pilosula, the rhizoma pinellinae praeparata, the ginger, the Chinese date, the honey-fried licorice root, the dried ginger, the coptis chinensis, the poria cocos and the bighead atractylodes rhizome according to the formula amount, adding water, and decocting for 3 times, wherein each time lasts for 1.5 hours, so as to obtain decoction;
s2) filtering the decoction obtained in the step S1, concentrating the filtrate into clear paste with the relative density of 1.10-1.20 (measured at 60 ℃), and drying to obtain extract powder.
Further, the preparation method also comprises the following steps:
mixing and stirring the extract powder, a purification reagent and water, performing water bath for 20-30 min at the temperature of 60-70 ℃, cooling, centrifuging, taking supernatant, concentrating and drying to obtain the modified bupleurum composition.
Further, the mass-volume ratio of the extract powder, the purification reagent and water is 1: (3-5): 3 (g: g: L).
In a content detection test, when β -1, 6-glucan is added, the content of liquiritin, baicalin, berberine hydrochloride, wogonoside, baicalein and glycyrrhetate ammonium salt can be improved, and the turbidity of the flavored bupleurum tenue aqueous solution is observed to be reduced in a dissolution test, so that β -1, 6-glucan can promote the solubilization of liquiritin, baicalin, berberine hydrochloride, wogonoside, baicalein and glycyrrhetate ammonium salt, and the liquiritin, baicalin, berberine hydrochloride, wogonoside, baicalein and glycyrrhetate ammonium salt are presumed to enter a β -1, 6-glucan aggregate through hydrogen bonds and hydrophobic effects among molecules respectively.
However, the aqueous solution of flavored bupleurum chinense has a certain turbidity, and in the content test, it is found that the flavored bupleurum chinense cannot become clear and transparent even if the amount of β -1, 6-glucan in the purification reagent is increased.
Further, the purification reagent is prepared from glutathione and β -1, 6-glucan according to the mass ratio of 1 (10-12).
Adding 30 wt% ethanol [ ethanol: purification reagent 2:1 (L: g) ], glutathione and β -1, 6-glucan into a reaction kettle, stirring at 40 ℃ for 2-5 h, and removing ethanol to obtain the purification reagent.
The invention provides a modified bupleurum tenue preparation, which comprises the modified bupleurum tenue composition and pharmaceutically available auxiliary materials.
Further, the modified bupleuri radix preparation is granule.
The invention provides modified bupleurum tenue particles, wherein each 1000g of modified bupleurum tenue particles are obtained by mixing the modified bupleurum tenue composition as claimed in any one of claims 1-6 and dextrin according to the mass ratio of 1: 0.8.
The invention also provides a preparation method of the modified bupleurum tenue granules, which comprises the following steps:
A. preparing a modified bupleurum composition:
s1) taking the bupleurum chinense, the scutellaria baicalensis, the codonopsis pilosula, the rhizoma pinellinae praeparata, the ginger, the Chinese date, the honey-fried licorice root, the dried ginger, the coptis chinensis, the poria cocos and the bighead atractylodes rhizome according to the formula amount, adding water, and decocting for 3 times, wherein each time lasts for 1.5 hours, so as to obtain decoction;
s2) filtering the decoction obtained in the step S1, concentrating the filtrate into clear paste with the relative density of 1.10-1.20 (measured at 60 ℃), and drying to obtain extract powder;
s3) mixing and stirring the extract powder, the purification reagent and water in the step S2, performing water bath for 20-30 min at 60-70 ℃, cooling, centrifuging, taking supernatant, concentrating and drying to obtain the modified radix bupleuri composition;
B. mixing the modified bupleuri radix composition obtained in the step A) with auxiliary materials, adding 70-80% ethanol, and granulating to obtain wet granules;
C. and D, drying the wet granules in the step B at the temperature of 80 ℃ to obtain the modified bupleurum tenue granules.
Compared with the prior art, the invention has the following beneficial effects:
(1) the bupleurum chinense, the scutellaria baicalensis, the codonopsis pilosula, the rhizoma pinellinae praeparata, the ginger, the Chinese date, the honey-fried licorice root, the dried ginger, the coptis chinensis, the poria cocos and the bighead atractylodes rhizome in the invention interact with each other to play a role in understanding shaoyang, harmonizing stomach, lowering adverse qi, tonifying spleen and relieving distension and fullness.
(2) In the invention, before the granules are formed, the extract is purified, so that the contents of active ingredients of liquiritin, baicalin, berberine hydrochloride, wogonoside, baicalein and ammonium glycyrrhetate in the raw material medicaments are improved, and the drug effect of the modified xiaochaihu granules is further improved.
Detailed Description
The present invention will be described in further detail with reference to the following examples. It should not be understood that the scope of the above-described subject matter of the present invention is limited to the following examples.
Example 1A modified bupleuri radix composition
The modified bupleurum composition is prepared from the following raw material medicaments in part by weight:
250g of bupleurum chinense; 167g of scutellaria baicalensis; 167g of codonopsis pilosula; 167g of rhizoma pinelliae praeparata; 167g of ginger; 500g of Chinese dates; prepared licorice root 100 g; 100g of dried ginger; 50g of coptis chinensis; 250g of poria cocos; 167g of white atractylodes rhizome.
The preparation method of the modified bupleurum composition comprises the following steps:
s1) taking the bupleurum chinense, the scutellaria baicalensis, the codonopsis pilosula, the rhizoma pinellinae praeparata, the ginger, the Chinese date, the honey-fried licorice root, the dried ginger, the coptis chinensis, the poria cocos and the bighead atractylodes rhizome according to the formula amount, adding water, and decocting for 3 times, wherein each time lasts for 1.5 hours, so as to obtain decoction;
s2) filtering the decoction obtained in the step S1, concentrating the filtrate into clear paste with the relative density of 1.10-1.20 (measured at 60 ℃), and drying to obtain extract powder, namely the modified bupleuri radix composition.
Example 2A modified bupleuri radix composition
The modified bupleurum composition is prepared from the following raw material medicaments in part by weight:
250g of bupleurum chinense; 167g of scutellaria baicalensis; 167g of codonopsis pilosula; 167g of rhizoma pinelliae praeparata; 167g of ginger; 500g of Chinese dates; prepared licorice root 100 g; 100g of dried ginger; 50g of coptis chinensis; 250g of poria cocos; 167g of white atractylodes rhizome.
The preparation method of the modified bupleurum composition comprises the following steps:
s1) taking the bupleurum chinense, the scutellaria baicalensis, the codonopsis pilosula, the rhizoma pinellinae praeparata, the ginger, the Chinese date, the honey-fried licorice root, the dried ginger, the coptis chinensis, the poria cocos and the bighead atractylodes rhizome according to the formula amount, adding water, and decocting for 3 times, wherein each time lasts for 1.5 hours, so as to obtain decoction;
s2) filtering the decoction obtained in the step S1, concentrating the filtrate into clear paste with the relative density of 1.10-1.20 (measured at 60 ℃), and drying to obtain extract powder;
s3) mixing the extract powder, the purifying reagent and water, stirring, performing water bath at 70 ℃ for 25min, cooling, centrifuging, taking the supernatant, concentrating and drying to obtain the modified bupleuri radix composition.
Wherein the mass volume ratio of the extract powder, the purification reagent and the water is 1: 5: 3 (g: g: L), and the purification reagent is prepared from glutathione and β -1, 6-glucan according to the mass ratio of 1: 10.
30 wt% ethanol [ ethanol: purification reagent 2:1 (L: g) ], glutathione and β -1, 6-glucan were added to the reaction vessel and stirred at 40 ℃ for 3.5 hours, after which ethanol was removed to obtain a purification reagent.
Example 3A modified bupleuri radix composition
The modified bupleurum composition is prepared from the following raw material medicaments in part by weight:
225g of bupleurum chinense; 180g of scutellaria baicalensis; 180g of codonopsis pilosula; rhizoma Pinelliae Preparata 180 g; 167g of ginger; 500g of Chinese dates; prepared licorice root 100 g; 91g of dried ginger; 50g of coptis chinensis; 245g of tuckahoe; 167g of white atractylodes rhizome.
The preparation method of the modified bupleurum composition comprises the following steps:
s1) taking the bupleurum chinense, the scutellaria baicalensis, the codonopsis pilosula, the rhizoma pinellinae praeparata, the ginger, the Chinese date, the honey-fried licorice root, the dried ginger, the coptis chinensis, the poria cocos and the bighead atractylodes rhizome according to the formula amount, adding water, and decocting for 3 times, wherein each time lasts for 1.5 hours, so as to obtain decoction;
s2) filtering the decoction obtained in the step S1, concentrating the filtrate into clear paste with the relative density of 1.10-1.20 (measured at 60 ℃), and drying to obtain extract powder;
s3) mixing the extract powder, the purifying reagent and water, stirring, bathing in water at 70 deg.C for 30min, cooling, centrifuging, collecting supernatant, concentrating, and drying to obtain the modified bupleuri radix composition.
Wherein the mass volume ratio of the extract powder, the purification reagent and the water is 1: 5: 3 (g: g: L), and the purification reagent is prepared from glutathione and β -1, 6-glucan according to the mass ratio of 1: 10.
30 wt% ethanol [ ethanol: purification reagent 2:1 (L: g) ], glutathione and β -1, 6-glucan were added to the reaction vessel and stirred at 40 ℃ for 2.5 hours, after which ethanol was removed to obtain a purification reagent.
Example 4A modified Xiaochaihu granule
Each 1000g of the modified bupleuri radix granules is prepared by mixing the modified bupleuri radix composition in example 1 and dextrin according to the mass ratio of 1: 0.8.
The preparation method of the modified Xiaochaihu granules comprises the following steps:
A. preparing a modified bupleurum composition:
B. mixing the modified bupleuri radix composition obtained in the step A) with auxiliary materials, adding 80% ethanol, and granulating to obtain wet granules;
C. and D, drying the wet granules in the step B at the temperature of 80 ℃ to obtain the modified bupleurum tenue granules.
Example 5A modified Xiaochaihu granule
Each 1000g of the modified bupleuri radix granule is prepared by mixing the modified bupleuri radix composition in example 2 and dextrin according to the mass ratio of 1: 0.8.
The preparation method of the modified Xiaochaihu granules comprises the following steps:
A. preparing a modified bupleurum composition:
B. mixing the modified bupleuri radix composition obtained in the step A) with auxiliary materials, adding 80% ethanol, and granulating to obtain wet granules;
C. and D, drying the wet granules in the step B at the temperature of 80 ℃ to obtain the modified bupleurum tenue granules.
Example 6A modified Xiaochaihu granule
Each 1000g of the modified bupleuri radix granule is prepared by mixing the modified bupleuri radix composition in example 3 and dextrin according to the mass ratio of 1: 0.8.
The preparation method of the modified Xiaochaihu granules comprises the following steps:
A. preparing a modified bupleurum composition:
B. mixing the modified bupleuri radix composition obtained in the step A) with auxiliary materials, adding 70% ethanol, and granulating to obtain wet granules;
C. and D, drying the wet granules in the step B at the temperature of 80 ℃ to obtain the modified bupleurum tenue granules.
Comparative example 1A modified Xiaochaihu granule
Similar to example 2, except that: the mass-volume ratio of the extract powder, the purifying reagent and the water in the modified bupleurum composition is 1: 1: 3 (g: g: L).
Comparative example 2, a modified Xiaochaihu granule
Similar to example 2, except that: the mass-volume ratio of the extract powder, the purifying reagent and the water in the modified bupleurum composition is 1: 9: 3 (g: g: L).
Comparative example 3A modified Xiaochaihu granule
Similar to example 2, except that: glutathione is not added into a purification reagent in the modified bupleurum composition, and the total mass of the purification reagent is not changed.
Comparative example 4A modified Xiaochaihu granule
Similar to example 2, except that β -1, 6-glucan was not added to the purification reagent in the modified bupleuri radix composition, and the total mass of the purification reagent was not changed.
Comparative example 5 modified Xiaochaihu granule
Similar to example 2, except that the purification reagent in the modified bupleuri radix composition is prepared from glutathione and β -1, 6-glucan according to the mass ratio of 1: 1.
Comparative example 6A modified Xiaochaihu granule
Similar to example 2, except that the purification reagent in the modified bupleuri radix composition is prepared from glutathione and β -1, 6-glucan according to the mass ratio of 1: 5.
Test one, dissolution test
The test method comprises the following steps: taking 10g of modified bupleuri radix granules respectively, adding 200mL of 80 ℃ hot water, stirring for 5min, and observing the conditions.
TABLE 1 observations
As can be seen from Table 1, the flavored Xiaochaihu granules of examples 5 to 6 are clear and transparent, insoluble substances are not seen with naked eyes, and the appearance of the flavored Xiaochaihu granules of comparative examples 1 to 6 is changed to different degrees.
Test two, content detection
2.1 test methods
(1) Chromatographic column conditions: agent ZORBAX Eclipse Plus C18(2.1 mm. times.50 mm, 1.8 μm); mobile phase acetonitrile-0.1% phosphoric acid; the flow rate is 0.4ml min < -1 >; the detection wavelength is 0-11 min, 270nm, 11-12 min and 254 nm; the column temperature is 35 ℃; the sample volume was 2. mu.l.
(2) Preparation of a standard curve: taking appropriate amount of liquiritin, baicalin, berberine hydrochloride, wogonoside, baicalein, and monoammonium glycyrrhizinate as reference substances, precisely weighing, and adding methanol to obtain stock solutions containing single components of liquiritin 0.294mg, baicalin 0.885mg, berberine hydrochloride 0.416mg, wogonoside 0.420mg, baicalein 0.235mg, and monoammonium glycyrrhizinate 0.234mg, respectively per 1 ml. Precisely transferring 3.0, 7.0, 3.0, 5.0, 2.0, 4.0ml of each of the 6 stock solutions, placing into a 25ml measuring flask, adding methanol for dissolving and diluting to obtain a mixed reference solution containing 0.03528mg of liquiritin, 0.2478mg of baicalin, 0.04992mg of berberine hydrochloride, 0.084mg of wogonin, 0.0188mg of baicalein and 0.03744mg of monoammonium glycyrrhizinate per 1ml, precisely sucking 0.5,1,2,4,5,8ml of the mixed reference solution, placing into a 10ml measuring flask, and measuring after methanol reaches the scale.
(3) Preparation of a sample: taking 0.5g of flavored bupleuri radix granules, precisely weighing, placing into a conical flask with a plug, adding 25ml of 70% ethanol, weighing, ultrasonically extracting (250W, 40kHz) for 45min, cooling, weighing again, supplementing the weight loss with 70% ethanol, filtering, and taking the filtrate. Each set of samples was tested 6 times.
2.2 Linear relationship
Liquiritin: Y-3.9894X-0.6651, r-0.9999;
baicalin: Y-7.9927X-166.76, r-0.9997;
berberine hydrochloride: Y-9.6145X-5.4412, r-0.9999;
wogonoside: Y-9.0784X-52.12, r-0.9995;
baicalein: Y-12.051X-5.2366, r-0.9999;
ammonium glycyrrhetate salt: Y-1.9943X-12.322 and r-0.9996.
Wherein Y is the peak area and X is the concentration of the reference substance.
2.3 Table 2 results of content measurement
In the quality standard of Xiaochaihu granules in the year version of Chinese pharmacopoeia 2015, only the content of baicalin is taken as a standard, and the invention measures liquiritin, baicalin, berberine hydrochloride, wogonin, baicalein and ammonium glycyrrhetate in the modified Xiaochaihu granules. As can be seen from Table 2, the contents of liquiritin, baicalin, berberine hydrochloride, wogonoside, baicalein and ammonium glycyrrhetate of example 5 were the highest.
Compared with example 5, the mass-volume ratio of the extract powder of the modified bupleurum chinense composition, the purifying reagent and the water in the comparative example 1 is 1: 1: 3 (g: g: L), that is, lowering the quality of the purification reagent, leads to lowering the content of each substance. Meanwhile, it was unexpectedly found that comparative example 2 increased the quality of the purification reagent and also resulted in a decrease in the content of each substance.
Compared with example 5, the purification reagent of the flavored bupleuri radix composition in comparative example 3 without adding glutathione, and the purification reagent of the flavored bupleuri radix composition in comparative example 4 without adding β -1, 6-glucan all reduced the content of each substance.
The difference in the mass ratio of glutathione to β -1, 6-glucan in comparative example 5 and comparative example 6 also resulted in a decrease in the content of each substance as compared with example 5, indicating that the dissolution of each substance was promoted only when the mass ratio of glutathione to β -1, 6-glucan was 1: 10.
Example 7A modified Xiaochaihu granule
The modified bupleurum composition is prepared from the following raw material medicaments in part by weight:
250g of bupleurum chinense; 167g of scutellaria baicalensis; 167g of codonopsis pilosula; 167g of rhizoma pinelliae praeparata; 167g of ginger; 500g of Chinese dates; prepared licorice root 100 g; 100g of dried ginger; 50g of coptis chinensis; 250g of poria cocos; 167g of white atractylodes rhizome.
The preparation method of the modified bupleurum composition comprises the following steps:
s1) taking the baical skullcap root, the pilose Asiabell root, the rhizoma pinellinae praeparata, the ginger, the Chinese date, the honey-fried licorice root, the dried ginger, the golden thread, the Indian buead and the largehead atractylodes rhizome according to the formula amount, adding water, and decocting for 3 times, wherein each time lasts for 1.5 hours, so as to obtain decoction;
s2) taking bupleurum chinense of the formula amount, crushing, adding into a distillation kettle, then adding 6 times of water and 0.05 times of sodium chloride, starting heating and distilling for 4h, wherein 1 time of water at 0 ℃ is added when boiling is kept for 30min, collecting condensate, and removing water to obtain bupleurum chinense oil;
s2) filtering the decoction obtained in the step S1, concentrating the filtrate into clear paste with the relative density of 1.10-1.20 (measured at 60 ℃), and drying to obtain extract powder;
s3) mixing the extract powder, the purifying reagent and water, stirring, water-bathing at 70 deg.C for 25min, cooling, centrifuging, collecting supernatant, adding bupleuri radix oil obtained in step S2, concentrating, and drying to obtain modified bupleuri radix composition.
Wherein the mass volume ratio of the extract powder, the purification reagent and the water is 1: 5: 3 (g: g: L), and the purification reagent is prepared from glutathione and β -1, 6-glucan according to the mass ratio of 1: 10.
30 wt% ethanol [ ethanol: purification reagent 2:1 (L: g) ], glutathione and β -1, 6-glucan were added to the reaction vessel and stirred at 40 ℃ for 3.5 hours, after which ethanol was removed to obtain a purification reagent.
Each 1000g of the modified bupleuri radix granule is prepared by mixing the modified bupleuri radix composition in example 2 and dextrin according to the mass ratio of 1: 0.8.
The preparation method of the modified Xiaochaihu granules comprises the following steps:
A. preparing a modified bupleurum composition:
B. mixing the modified bupleuri radix composition obtained in the step A) with auxiliary materials, adding 80% ethanol, and granulating to obtain wet granules;
C. and D, drying the wet granules in the step B at the temperature of 80 ℃ to obtain the modified bupleurum tenue granules.
Test three, content detection of control example
TABLE 3 results of content measurement
In the early grope stage, the saikosaponin components cannot be detected even after the flavored bupleurum tenue composition is purified, and the analysis reason may be that the saikosaponin is volatilized or decomposed in the preparation process. In order to improve the condition, the bupleurum root is separately extracted, and the saikosaponin components can be detected by detection, and the mode of combining multiple boiling and cooling can generate temperature difference, so that the heat transfer direction between the inside and the outside of cells is continuously changed, the decomposition of the saikosaponin in the bupleurum root caused by long-time heating is avoided, and the fragrance is also prevented from being influenced by the coking of the bupleurum root due to overheating.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (10)
1. The modified bupleurum composition is characterized by being prepared from the following raw material medicaments in part by weight:
225-275 g of bupleurum chinense;
150-200 g of scutellaria baicalensis;
150-200 g of codonopsis pilosula;
150-200 g of rhizoma pinelliae praeparata;
150-200 g of ginger;
475-525 g of Chinese dates;
75-125 g of honey-fried licorice root;
75-125 g of dried ginger;
25-75 g of coptis chinensis;
225-275 g of tuckahoe;
150-200 g of bighead atractylodes rhizome.
2. The modified bupleurum composition as claimed in claim 1, which is prepared from the following raw materials (by weight):
250g of bupleurum chinense;
167g of scutellaria baicalensis;
167g of codonopsis pilosula;
167g of rhizoma pinelliae praeparata;
167g of ginger;
500g of Chinese dates;
prepared licorice root 100 g;
100g of dried ginger;
50g of coptis chinensis;
250g of poria cocos;
167g of white atractylodes rhizome.
3. The modified bupleuri radix composition according to claim 1 or 2, wherein the preparation method comprises the following steps:
s1) taking the bupleurum chinense, the scutellaria baicalensis, the codonopsis pilosula, the rhizoma pinellinae praeparata, the ginger, the Chinese date, the honey-fried licorice root, the dried ginger, the coptis chinensis, the poria cocos and the bighead atractylodes rhizome according to the formula amount, adding water, and decocting for 3 times, wherein each time lasts for 1.5 hours, so as to obtain decoction;
s2) filtering the decoction obtained in the step S1, concentrating the filtrate into clear paste with the relative density of 1.10-1.20 (measured at 60 ℃), and drying to obtain extract powder.
4. The modified bupleuri radix composition of claim 3, wherein the preparation method further comprises the steps of:
mixing and stirring the extract powder, a purification reagent and water, performing water bath for 20-30 min at the temperature of 60-70 ℃, cooling, centrifuging, taking supernatant, concentrating and drying to obtain the modified bupleurum composition.
5. The modified bupleuri radix composition of claim 4, wherein the mass-to-volume ratio of the extract powder, the purification reagent and the water is 1: (3-5): 3 (g: g: L).
6. The modified bupleurum chinense composition as claimed in claim 4, wherein the purifying reagent is prepared from glutathione and β -1, 6-glucan in a mass ratio of 1 (10-12).
7. A modified bupleuri radix preparation, comprising the modified bupleuri radix composition of any one of claims 1-6 and pharmaceutically acceptable excipients.
8. The modified bupleuri radix formulation of claim 7, wherein said modified bupleuri radix formulation is a granule.
9. Modified Xiaochaihu granules are characterized in that each 1000g of modified Xiaochaihu granules are obtained by mixing the modified Xiaochaihu composition as claimed in any one of claims 1 to 6 and dextrin according to the mass ratio of 1: 0.8.
10. A preparation method of modified Xiaochaihu granules is characterized by comprising the following steps:
A. preparing a modified bupleurum composition:
s1) taking the bupleurum chinense, the scutellaria baicalensis, the codonopsis pilosula, the rhizoma pinellinae praeparata, the ginger, the Chinese date, the honey-fried licorice root, the dried ginger, the coptis chinensis, the poria cocos and the bighead atractylodes rhizome according to the formula amount, adding water, and decocting for 3 times, wherein each time lasts for 1.5 hours, so as to obtain decoction;
s2) filtering the decoction obtained in the step S1, concentrating the filtrate into clear paste with the relative density of 1.10-1.20 (measured at 60 ℃), and drying to obtain extract powder;
s3) mixing and stirring the extract powder, the purification reagent and water in the step S2, performing water bath for 20-30 min at 60-70 ℃, cooling, centrifuging, taking supernatant, concentrating and drying to obtain the modified radix bupleuri composition;
B. mixing the modified bupleuri radix composition obtained in the step A) with auxiliary materials, adding 70-80% ethanol, and granulating to obtain wet granules;
C. and D, drying the wet granules in the step B at the temperature of 80 ℃ to obtain the modified bupleurum tenue granules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911312896.6A CN110974927B (en) | 2019-12-18 | 2019-12-18 | Modified Xiaochaihu granules and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911312896.6A CN110974927B (en) | 2019-12-18 | 2019-12-18 | Modified Xiaochaihu granules and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110974927A true CN110974927A (en) | 2020-04-10 |
| CN110974927B CN110974927B (en) | 2021-09-10 |
Family
ID=70095901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911312896.6A Active CN110974927B (en) | 2019-12-18 | 2019-12-18 | Modified Xiaochaihu granules and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110974927B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113281449A (en) * | 2021-04-21 | 2021-08-20 | 广东志道医药科技有限公司 | Thin-layer identification method of bupleurum tenue preparation |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103805578A (en) * | 2013-12-23 | 2014-05-21 | 湖南鸿鹰生物科技有限公司 | Beta-dextranase with good heat stability |
| CN103800916A (en) * | 2014-02-13 | 2014-05-21 | 重庆市中药研究院 | Glucan inclusion compound of water-insoluble small molecule drug and preparation method thereof |
| CN106511925A (en) * | 2016-11-10 | 2017-03-22 | 东莞市中医院 | Modified common goldenrop granules as well as preparation method and applications thereof |
| CN106692985A (en) * | 2016-12-21 | 2017-05-24 | 重庆市中药研究院 | Chrysophanol glucan clathrate compound and application thereof |
| CN108440683A (en) * | 2018-03-30 | 2018-08-24 | 福建师范大学 | A kind of glucan curcumin inclusion compound and preparation method thereof |
| CN108936178A (en) * | 2018-07-31 | 2018-12-07 | 中科特膳（天津）医用食品有限公司 | It is a kind of for preventing and treating the solid beverage and preparation method thereof of dysmenorrhea and gynaecological imflammation |
-
2019
- 2019-12-18 CN CN201911312896.6A patent/CN110974927B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103805578A (en) * | 2013-12-23 | 2014-05-21 | 湖南鸿鹰生物科技有限公司 | Beta-dextranase with good heat stability |
| CN103800916A (en) * | 2014-02-13 | 2014-05-21 | 重庆市中药研究院 | Glucan inclusion compound of water-insoluble small molecule drug and preparation method thereof |
| CN106511925A (en) * | 2016-11-10 | 2017-03-22 | 东莞市中医院 | Modified common goldenrop granules as well as preparation method and applications thereof |
| CN106692985A (en) * | 2016-12-21 | 2017-05-24 | 重庆市中药研究院 | Chrysophanol glucan clathrate compound and application thereof |
| CN108440683A (en) * | 2018-03-30 | 2018-08-24 | 福建师范大学 | A kind of glucan curcumin inclusion compound and preparation method thereof |
| CN108936178A (en) * | 2018-07-31 | 2018-12-07 | 中科特膳（天津）医用食品有限公司 | It is a kind of for preventing and treating the solid beverage and preparation method thereof of dysmenorrhea and gynaecological imflammation |
Non-Patent Citations (4)
| Title |
|---|
| 刘蓝天,等: "酵母β-葡聚糖的研究进展及应用", 《食品工业》 * |
| 李红,等: "大黄酚复合物的制备方法研究", 《天然产物研究与开发》 * |
| 陈雪剑,等: "加味小柴胡汤抗胃溃疡有效物质部位的血清药物化学研究", 《中国中药杂志》 * |
| 黄湘谚,等: "加味小柴胡汤治疗肝胃不和型慢性胃炎疗效观察", 《湖北中医杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113281449A (en) * | 2021-04-21 | 2021-08-20 | 广东志道医药科技有限公司 | Thin-layer identification method of bupleurum tenue preparation |
| CN113281449B (en) * | 2021-04-21 | 2022-04-08 | 广东志道医药科技有限公司 | Thin-layer identification method of bupleurum tenue preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110974927B (en) | 2021-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | A systematic review on botany, processing, application, phytochemistry and pharmacological action of Radix Rehmnniae | |
| CN106324174A (en) | Quality standard for traditional Chinese medicine formula granules | |
| CN101513519B (en) | Chinese medicinal composition for invigorating Qi and nourishing blood, preparation method and quality control method thereof | |
| CN102416139B (en) | Chinese medicine composition for treating breast diseases | |
| CN103071006B (en) | Preparation method and quality inspection method of traditional Chinese medicine for treating kidney failure | |
| AU2015345884B2 (en) | Drug or health care product preventing or treating liver and kidney damage-related diseases and use thereof | |
| CN101496870B (en) | Chinese medicinal composition for resolving phlegm and suppressing cough as well as preparation method and quality control method thereof | |
| CN113018405B (en) | Traditional Chinese medicine composition for treating post-stroke depression and preparation method thereof | |
| CN102120015A (en) | Traditional Chinese medicine for soothing liver and dispersing depressed vital energy and soothing nerves and sedating mind, and preparation method and quality standard thereof | |
| CN100525809C (en) | Medicinal composition of milkvetch root, chinaroot greenbrier and Hong Jingtian and its making method | |
| CN115779983A (en) | Ion exchange technology-based traditional Chinese medicine decoction potassium removal process | |
| CN110974927B (en) | Modified Xiaochaihu granules and preparation method thereof | |
| CN103349707B (en) | Method for preparing eight-treasure granules | |
| CN1977885B (en) | Antihepatitis medicinal composition | |
| CN102920964B (en) | Traditional Chinese medicine preparation for curing cough | |
| CN102526230B (en) | Traditional Chinese composition for curing liver disease and preparation method, quality detection method and application thereof | |
| CN115184492B (en) | Fingerprint spectrum establishment method of qing Jin Yi gas particles and component content determination method thereof | |
| CN110721289A (en) | Preparation method of Renzhu stomach-invigorating granules | |
| CN104666406A (en) | Pharmaceutical composition for treating intestinal cancer and cervical cancer and preparation method of pharmaceutical composition | |
| CN1977886B (en) | Medicinal composition of oxymatrine, ganoderma lucidum and astragalus | |
| Song et al. | Protective effect of korean medicinal plants on ethanol-induced cytotoxicity in HepG2 Cells | |
| WO2019205959A1 (en) | Pharmaceutical composition for treating epilepsy and convulsions, infantile convulsions and facial spasms and preparation method therefor | |
| CN111714465B (en) | Jiuwei Shuangjie soft capsule and preparation method thereof | |
| CN109966440A (en) | A kind of Chinese medicine with sugar amount transformation | |
| CN115025158A (en) | Extract of Chinese medicinal herb powder and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |